Osteogenesis imperfecta (OI) is a connective tissue disorder characterized by bone fragility,
low bone mass, and bone deformities. The majority of cases are caused by autosomal …

… of the mutant α2(I) collagen allele in type IV Osteogenesis Imperfecta fibroblasts. A molecular
approach to therapeutics of dominant negative disorders. J Clin Invest 97:448–454, 1996. …

… Osteogenesis imperfecta (OI) is a rare clinically and genetically heterogeneous systemic
disorder of bone and connective tissue characterized by bone fragility and physical findings …

Introduction: Osteogenesis imperfecta (OI) is a heritable disease characterized by bone
fragility. A wide range of clinical severity and heterogeneity of the molecular defects is reported. …

… 1 Gene therapy strategies to target mutant collagen transcripts. (a) Antisense
oligodeoxyribonucleotides (ODNs) are single-stranded DNA molecules that upon their entry into a …

… Osteogenesis imperfecta (01) is a skeletal disorder of remarkable clinical variability
characterized by bone fragility, osteopenia, variable degrees of short stature, and progressive …

… Osteogenesis imperfecta (OI) is the most common bone genetic disorder and it is
characterized by bone brittleness and various degrees of growth disorder. Clinical severity varies …

… Osteogenesis imperfecta is the term used to describe a group of inherited disorders … As
new genes for osteogenesis imperfecta have been discovered a new classification system has …

… the OI phenotype may be a more promising therapeutic strategy than correction of the structural
… A summary of the current experimental strategies for OI therapy is presented in Figure 3. …

… for osteogenesis imperfecta as a collagen-related disorder. The more prevalent autosomal
dominant forms of osteogenesis imperfecta are … of dominant osteogenesis imperfecta include …